Zoetis Inc. (ZTS) Stake Boosted by Rhumbline Advisers
Rhumbline Advisers increased its stake in Zoetis Inc. (NYSE:ZTS) by 2.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,065,495 shares of the company’s stock after buying an additional 25,712 shares during the period. Rhumbline Advisers’ holdings in Zoetis were worth $66,466,000 as of its most recent filing with the SEC.
Several other institutional investors also recently bought and sold shares of ZTS. Gladstone Capital Management LLP bought a new position in Zoetis during the second quarter valued at about $3,134,000. Ameriprise Financial Inc. increased its stake in Zoetis by 21.1% in the first quarter. Ameriprise Financial Inc. now owns 1,614,416 shares of the company’s stock valued at $86,167,000 after buying an additional 281,139 shares during the last quarter. Harbour Capital Advisors LLC increased its stake in Zoetis by 19.8% in the first quarter. Harbour Capital Advisors LLC now owns 20,005 shares of the company’s stock valued at $1,068,000 after buying an additional 3,300 shares during the last quarter. Hermes Investment Management Ltd. increased its stake in Zoetis by 80.3% in the second quarter. Hermes Investment Management Ltd. now owns 236,350 shares of the company’s stock valued at $14,744,000 after buying an additional 105,276 shares during the last quarter. Finally, AXA increased its stake in Zoetis by 0.8% in the first quarter. AXA now owns 242,831 shares of the company’s stock valued at $12,960,000 after buying an additional 1,900 shares during the last quarter. 94.51% of the stock is owned by hedge funds and other institutional investors.
Shares of Zoetis Inc. (ZTS) opened at 59.74 on Friday. Zoetis Inc. has a 1-year low of $46.86 and a 1-year high of $63.85. The firm’s 50 day moving average price is $62.30 and its 200-day moving average price is $57.96. The company has a market capitalization of $29.22 billion, a P/E ratio of 33.77 and a beta of 1.02.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.53. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The firm had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.27 billion. During the same quarter last year, the business posted $0.49 earnings per share. The firm’s revenue was up 5.0% compared to the same quarter last year. Analysts expect that Zoetis Inc. will post $2.34 EPS for the current year.
Several research firms recently commented on ZTS. Cowen and Company set a $70.00 price objective on Zoetis and gave the stock a “buy” rating in a report on Monday, July 17th. Deutsche Bank AG reiterated a “buy” rating and issued a $65.00 price objective (up from $62.00) on shares of Zoetis in a report on Monday, July 17th. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a report on Tuesday, June 20th. Hilliard Lyons began coverage on Zoetis in a report on Tuesday, June 20th. They issued a “buy” rating and a $77.00 price objective for the company. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $65.00 price objective on shares of Zoetis in a report on Friday, July 21st. One analyst has rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $64.78.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.